Xeris Biopharma Holdings, Inc. (XERS)

In the past six months, Xeris Biopharma Holdings, Inc.'s stock price has been impacted by several events. Strong financial performance, including exceeding revenue guidance and positive Adjusted EBITDA, likely contributed to stock appreciation. Analysts have issued various ratings, with a consensus of "Moderate Buy" and an average twelve-month target price of $9.50. The company strengthened its intellectual property portfolio with a new Orange Book-listed U.S. patent for Recorlev® and a composition of matter patent for XP-8121. There has been notable insider selling, which could be perceived negatively by investors. The share price as of January 9, 2026, was $7.93, representing a significant increase from $3.40 on January 10, 2025, and the stock experienced a gap up before market open on January 8, 2026.

Information directly pertaining to the seasonality of demand for Xeris Biopharma Holdings, Inc.'s products and services is not explicitly detailed in the provided search results. However, a seasonal chart analysis for XERS stock suggests a period of seasonal strength for the Healthcare sector, which runs from April to December. This analysis indicates a "Buy Date of April 19 and a Sell Date of July 11" has historically resulted in positive returns for the stock. This refers to stock performance seasonality and not necessarily the seasonality of patient demand for their specific therapies.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for individuals with chronic endocrine and neurological diseases, operating within the Pharmaceuticals sector and the Drug Discovery and Other Devices and Supplies industries. The company improves patient lives through innovative, ready-to-use therapeutic medicines, leveraging its proprietary formulation technologies, XeriSol and XeriJect, to create liquid-stable injectable and infusible drugs. Its major commercial products include Gvoke® for severe hypoglycemia, Recorlev® for Cushing's syndrome, and Keveyis® for Primary Periodic Paralysis. Xeris also has a pipeline of development programs, notably XP-8121 for hypothyroidism.

Xeris Biopharma Holdings, Inc. is headquartered in Chicago, Illinois, United States, and primarily focuses on developing and commercializing therapies in the United States. Its stock is traded on exchanges in the UK and Germany, indicating an international investor base rather than a broad commercial presence in those regions.

In the past year, Xeris Biopharma Holdings, Inc. has generally maintained a positive brand reputation, primarily driven by strong financial performance and advancements in its product pipeline. The company reported record fourth-quarter and full-year 2025 total revenue, exceeding guidance, and its key products, Recorlev and Gvoke, showed significant revenue growth. Analysts have largely given the stock "Moderate Buy" or "Strong Buy" recommendations, with several maintaining or increasing price targets. The strengthening of its intellectual property portfolio also contributes positively to its reputation. Insider selling could be viewed with caution by some investors.

Xeris Biopharma Holdings, Inc. is majority-owned by institutional investors, including BlackRock, Inc., Vanguard Group Inc., and D. E. Shaw & Co., Inc. Individual investors collectively own approximately 26.88% of the company's shares, with notable individual and insider owners including Redmile Group LLC and Paul R. Edick. Insider ownership stood at 14.72% as of a recent report.